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Abstract
Background: A large body of literature suggests that certain polysaccharides affect immune system function. Much
of this literature, however, consists of in vitro studies or studies in which polysaccharides were injected. Their
immunologic effects following oral administration is less clear. The purpose of this systematic review was to
consolidate and evaluate the available data regarding the specific immunologic effects of dietary polysaccharides.
Methods: Studies were identified by conducting PubMed and Google Scholar electronic searches and through
reviews of polysaccharide article bibliographies. Only articles published in English were included in this review. Two
researchers reviewed data on study design, control, sample size, results, and nature of outcome measures.
Subsequent searches were conducted to gather information about polysaccharide safety, structure and
composition, and disposition.
Results: We found 62 publications reporting statistically significant effects of orally ingested glucans, pectins,
heteroglycans, glucomannans, fucoidans, galactomannans, arabinogalactans and mixed polysaccharide products in
rodents. Fifteen controlled human studies reported that oral glucans, arabinogalactans, heteroglycans, and
fucoidans exerted significant effects. Although some studies investigated anti-inflammatory effects, most studies
investigated the ability of oral polysaccharides to stimulate the immune system. These studies, as well as safety and
toxicity studies, suggest that these polysaccharide products appear to be largely well-tolerated.
Conclusions: Taken as a whole, the oral polysaccharide literature is highly heterogenous and is not sufficient to
support broad product structure/function generalizations. Numerous dietary polysaccharides, particularly glucans,
appear to elicit diverse immunomodulatory effects in numerous animal tissues, including the blood, GI tract and
spleen. Glucan extracts from the Trametes versicolor mushroom improved survival and immune function in human
RCTs of cancer patients; glucans, arabinogalactans and fucoidans elicited immunomodulatory effects in controlled
studies of healthy adults and patients with canker sores and seasonal allergies. This review provides a foundation
that can serve to guide future research on immune modulation by well-characterized polysaccharide compounds.
Background
Polysaccharide-rich fungi and plants have been
employed for centuries by cultures around the world for
their dietary and medicinal benefits [1-5]. Often thought
to merely support normal bowel function and blood
glucose and lipid levels [6-8], certain polysaccharides
have attracted growing scientific interest for their ability
to exert marked effects on immune system function,
inflammation and cancers [9-11]. Many of these chemi-
cally and structurally diverse, non- to poorly-digestible
polysaccharides have been shown to beneficially affect
one or more targeted cellular functions in vitro [11-16],
but much of the in vivo literature consists of studies in
which polysaccharides were injected [1,2]. For clinicians
and scientists interested in immunologic effects follow-
ing dietary intake, the value of such studies is uncertain.
Polysaccharides that elicit effects in vitro or by injection
may be ineffective or have different effects when taken
orally [17]. We thus decided to conduct a systematic
review to evaluate the specific immunologic effects of
dietary polysaccharide products on rodents and human
subjects. * Correspondence: jramberg@mannatech.com
Mannatech™, Incorporated, 600 S. Royal Lane, Suite 200, Coppell, TX 75019
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Literature review
Studies were identified by conducting electronic
searches of PubMed and Google Scholar from their
inception to the end of October 2009. The reference
lists of the selected articles were checked for additional
studies that were not originally found in the search.
Study selection and data extraction
The following search terms were combined with the
term polysaccharide: dietary AND immune, or oral
AND immune, or dietary AND inflammation, or oral
AND inflammation. When specific polysaccharides or
polysaccharide-rich plants and fungi were identified,
further searches were conducted using their names with
the same search terms. Studies were selected based on
the following inclusion criteria:
1. Rodent or human studies
2. The presence of test group and control group
(using either placebo, crossover, sham, or normal care)
3. Studies reporting statistically significant immuno-
modulatory effects
4. English language
5. Studies published up to October 2009.
Two researchers (JER, EDN) reviewed the list of
unique articles for studies that fit the inclusion criteria.
Uncertainties over study inclusion were discussed
between the researchers and resolved through consen-
sus. Searches were then conducted to obtain specific
polysaccharide product information: safety (using the
search terms: toxicity, NOAEL, LD50), composition and
structure, and disposition.
Quality assessment
Each study was assessed as to whether or not it reported
a significant outcome measure for the polysaccharide
intervention group.
Results
A total of 62 rodent publications (Tables 1, 2 and 3) and
15 human publications (Table 4) were deemed appropri-
ate for inclusion in this review. Available structural and
compositional information for these immunomodulatory
polysaccharides are provided in Table 5 and safety infor-
mation is provided in Table 6. The majority of animal
studies explored models in which animals were injected
or implanted with cancer cells or tumors, were healthy,
or were exposed to carcinogens. Other studies investi-
gated immunodeficient, exercise-stressed, aged animals,
or animals exposed to inflammatory agents, viruses, bac-
terial pathogens, pathogenic protozoa, radiation or
mutagens. Human studies assessed immunomodulatory
effects in healthy subjects, or patients with cancers, sea-
sonal allergic rhinitis or aphthous stomatitis. Because of
the limited number of human studies, we included some
promising open-label controlled trials. Human study
durations ranged from four days to seven years; daily
doses ranging from 100-5,400 mg were reported to be
well-tolerated.
A number of studies in healthy human adults demon-
strated immune stimulating effects of oral polysacchar-
ides. Arabinogalactans from Larix occidentalis (Western
larch) were shown in RCTs to increase lymphocyte pro-
liferation and the number of CD8+ lymphocytes [18]
and to increase the IgG subtype response to pneumo-
coccal vaccination [19]. A furanose extract from Panax
quiquefolium (North American ginseng) was shown in
an RCT of healthy older adults to decrease the incidence
of acute respiratory illness and symptom duration [20].
Finally, an RCT of healthy adults consuming Undaria
pinnatifida (wakame) fucoidans found both immune sti-
mulating and suppressing effects, including increased
stromal-derived factor-1, IFN-g, CD34+ cells and
CXCR4-expressing CD34+ cells and decreased blood
leukocytes and lymphocytes [21].
Studies in healthy animals showed a number of
immune stimulating effects of various glucan products
from Agaricus subrufescens (A. blazei) (aqueous extracts
[22], aqueous extracts with standardized b-glucans [23],
a-1,6 and a-1,4 glucans [24], and whole plant powders
[25]); Lentinula edodes (shiitake) (lentinan [26] and b-
glucans [27]); Saccharomyces cerevisiae (b-1,3-glucans
[27,28]); Laminaria digitata (laminarin [29]); Sclerotium
rofsii (glucan phosphate [29]); Sclerotinia sclerotiorum
(SSG [30]); and Phellinus linteus (powder [31] and aqu-
eous, alcohol-precipitated extract [32]). A furanose
extract from P. quiquefolium and pectins from
Buplerum falcatum and Malus (apple) spp. have also
been shown to enhance immune function in healthy
young animals [33-35]. Cyamopsis tetragonolobus galac-
tomannan (guar gum) or highly methoxylated pectin
feeding exerted numerous stimulating effects on anti-
body production in older animals [36].
Evidence for the effectiveness of oral polysaccharides
against infection and immune challenges has been
mainly demonstrated in animals. Immune stimulating
effects have been shown in resting and exercise-stressed
animals with thioglycollate, clodronate, or HSV-1 injec-
tions fed Avena (oat) spp. soluble glucans [37-41]; ani-
mals injected with or fed E. vermiformis and fed Avena
spp. particulate glucans [42,43]; animals with E. coli
injections fed L. digitata glucans (laminarin) [44]; ani-
mals with HSV injections fed U. pinnatifida fucoidans
[45]; animals with Staphylococcus aureus or Candida
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Source Extract Animal Dose/day Duration
of study
Treatment Effects Reference
Agaricus
(A. blazei)
subrufescens
a-1,6 and
a-1,4
glucans
8-week ♀ C3H/
He mice (5/
group)
100 mg/kg
IG every 3
days
1 month Healthy animals ↑ #s splenic T lymphocytes
(Thy1.2, CD4+ and CD8+)
[24]
Aqueous 7-9-week ♂
Balb/cByJ mice
(40/group)
1 ml 0.45N,
0.6N, or 3N
aqueous
extract
2 months All doses ↑ serum IgG levels,
CD3+ T cell populations and
PML phagocytic activity
[22]
7-9-week male
Balb/cByJ mice
(40/group)
1 ml 0.45N,
0.6N, or 3N
aqueous
extract
10 weeks IP injection of OVA at 4
weeks
0.6N and 3N ↑ levels of OVA-
specific serum IgG 28 days
post-immunization; all doses
↑ delayed-type
hypersensitivity and TNF-a
secreted from splenocytes at
10 weeks; 0.6N ↑ splenocyte
proliferation at 10 weeks
5-6 -week ♀
BALB/cHsdOla
mice (8/group
×2 )
One 200 μl
extract day
1, orogastric
intubation
1 week Injected IP fecal solution day
2
↓ CFU in blood of mice with
severe peritonitis & improved
overall survival rate in all
peritonitis groups
[46]
6-week BALB/c
nu/nu mice (7/
group)
2.5 mg
extract days
20-41,
drinking
water
41 days Injected SC Sp-2 myeloma
cells day 1
↓ tumor size & weight after
21 days treatment
[65]
Aqueous,
acid treated
6-week ♀
C57BL/6 mice
(10/group)
20, 100 or
500 μg/ml,
drinking
water
9 days Injected IP human ovarian
cancer cells day 1
500 μg/ml ↓ tumor weight [66]
20, 100 or
500 μg/ml,
drinking
water
3 weeks Injected IV murine lung
cancer (3LL) cells
100 & 500 μg/ml ↓ #s
metastatic tumors
Aqueous,
with 200
ng/day
b-glucan
6-week ♀
BALB/c mice
(10/group)
200 ng days
5-21
3 weeks Injected Meth A tumor cells
day 1
↓ tumor size & weight [23]
2 weeks Injected Meth A tumor cells ↑ cytotoxic T lymphocyte
activity & spleen cell IFN-a
protein
300 mg 5 days Healthy animals ↑ splenic NK cell activity
Avena spp. b-glucans
(particulate)
6-7 -week ♀
C57BL/6 mice
(7/group)
3 mg every
48 h, days
1-3
1 month Oral E. vermiformis oocytes
day 10
↓ E. vermiformis fecal oocyte
#s; increased intestinal anti-
merozoite IgA; ↓ # of IL-4-
secreting MLN cells
[42]
3m go n
alternating
days, days
1-10
22 days Injected IP Eimeria
vermiformis day 10
↓ E. vermiformis fecal oocyte
#s; ↑ anti-merozoite intestinal
IgA
[43]
b-glucans
(soluble)
4-week ♂ CD-1
mice (24/
group)
0.6 mg/ml
68% b-
glucan,
drinking
water
1 month Resting or exercise-stressed
(days 8-10) animals
administered HSV-1 IN
day 10
↓ morbidity in resting and
exercise-stressed animals; ↓
mortality in exercise-stressed
animals; pre-infection, ↑ Mø
anti-viral resistance in resting
and exercise-stressed animals
[38]
~3.5 mg
days
1-10,
drinking
water
Resting or exercise-stressed
(days 5-10) animals
administered HSV-1 IN
day 10
Pre-infection, ↑ Mø antiviral
resistance in resting animals
[41]
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4-week ♂ CD-1
mice (10/
group)
0.6 mg/ml
68% b-
glucan,
drinking
water
10 days Resting animals or animals
exposed to a bout of
fatiguing exercise days 8-10
or moderate exercise days 5-
10, injected IP with
thioglycollate on day 10
↑ neutrophil mobilization in
resting & moderately
exercised animals; ↑
neutrophil respiratory burst
activity in resting and
fatiguing exercised animals
[37]
4-week ♂ CD-1
mice (19-30/
group)
0.8 mg/ml
50% b-
glucan, days
1-10,
drinking
water
1 month Resting or exercise-stressed
(days 8-10) animals
administered IN clodronate-
filled liposomes to deplete
Mø days 8 & 14 & infected IN
with HSV-1 day 10
↓ morbidity, mortality,
symptom severity in
exercise-stressed animals,
without Mø depletion
[40]
4-week ♂ CD-1
mice (20/
group)
Resting or exercise-stressed
(days 8-10) animals
administered HSV-1 IN day
10
↓ morbidity in exercise-
stressed & resting animals; ↓
mortality in exercise-stressed
animals
[39]
Ganoderma
lucidum
Aqueous 7-week ♂ CD-1
mice (26/
group)
5% of diet 5 months Injected IM DMH once a
week, weeks 1-10
↓ aberrant crypt foci per
colon, tumor size, cell
proliferation, nuclear staining
of b-catenin
[69]
4-8-week
BALB/c mice
(10/group)
50, 100 or
200 mg/kg,
oral
10 days Injected SD Sarcoma 180
cells
↓ of tumor weight was dose
dependent: 27.7, 55.8, 66.7%,
respectively
[67]
Ganoderma
lucidum
(mycelia)
Aqueous 7-week ♂
F344/Du Crj
rats (16/group)
1.25% or
2.5% of diet
6 months Injected SC AOM once a
week, weeks2-5
Both doses ↓ colonic
adenocarcinoma incidence;
2.5% ↓ total tumor incidence;
both doses ↓ nuclear
staining of b-catenin and cell
proliferation
[68]
Ganoderma
tsugae
Aqueous 8-week ♀
BALB/cByJNarl
mice (14/
group)
0.2-0.4% of
diet (young
fungi); 0.33
or 0.66% of
diet (mature
fungi)
5 weeks Injected IP OVA days 7, 14,
21; aerosolized OVA twice
during week 4
In splenocytes, both doses of
both extracts ↑ IL-2 and IL-2/
IL-4 ratios, 0.2% young
extract and 0.66% mature
extract ↓ IL-4; in Mø, 0.66%
mature extract ↑ IL-1b, both
doses of both extracts ↑ IL-6
[53]
Grifola frondosa D fraction Mice: 1) ICR, 2)
C3H/HeN, 3)
CDF1 (10/
group)
1.5 mg every
other day,
beginning
day 2
13 days Implanted SC: 1) Sarcoma-
180, 2) MM-46 carcinoma, or
3) IMC carcinoma cells
↓ tumor weight & tumor
growth rate: 1) 58%, 2) 64%,
and 3) 75%, respectively
[71]
5-week ♂
BALB/c mice
(10/group)
2 mg,
days 15-30
45 days Injected in the back with 3-
MCA, day 1
↓ (62.5%) # of animals with
tumors; ↑ H202 production
by plasma Mø; ↑ cytotoxic T
cell activity
[72]
Hordeum
vulgare
b-1,3;1,4 or
b-1,3;1,6-D-
glucans
Athymic nu/nu
mice
(4-12/group)
40 or 400 μg
IG for
4 weeks
31 weeks Mice with human xenografts
(SKMel28 melanoma, A431
epidermoid carcinoma, BT474
breast carcinoma, Daudi
lymphoma, or LAN-1
neuroblastoma) ± mAb (R24,
528, Herceptin, Rituximab, or
3F8, respectively) therapy
twice weekly
400 μg + mAb ↓ tumor
growth & ↑ survival; higher
MW ↓ tumor growth rate for
both doses
[75]
b-1,3;1,4-D-
glucans
Athymic BALB/
c mice
4, 40, or 400
μg for 3-
4 weeks
1 month Mice with neuroblastoma
(NMB7, LAN-1, or SK-N-ER)
xenografts, ± 3F8 mAb
therapy twice weekly
40 and 400 μg doses + mAB
↓ tumor growth; 400 μg
dose ↑ survival. Serum NK
cells required for effects on
tumor size
[76]
C57BL/6 WT
and CR3-
deficient mice
(10/group)
0.4 mg for
3 weeks
100 days Injected SC RMA-S-MUC1
lymphoma cells day 1 ± IV
14.G2a or anti-MUC1 mAb
every 3rd day
±mAB ↓ tumor diameter; ↑
survival
[73]
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b-glucans ♀ Fox Chase
ICR immune-
deficient (SCID)
mice (9/group)
400 μg
days 1-29
50 days Mice with human (Daudi,
EBV-BLCL, Hs445, or
RPMI6666) lymphoma
xenografts, ± Rituximab mAb
therapy twice weekly
+mAB ↓ tumor growth and
↑ survival
[74]
Laminaria
digitata
Laminarin ♂ ICR/HSD
mice (3/group)
1 mg 1 day Healthy animals ↑ Mø expression of Dectin-1
in GALT cells; ↑ TLR2
expression in Peyer’s patch
dendritic cells
[29]
♂ Wistar rats
(7/group)
5% of diet
days 1-4,
10% of diet
days 5-25
26 days Injected IP E. coli LPS day 25 ↓ liver ALT, AST, and LDH
enzyme levels; ↑ ED2-positive
cells, .↓ peroxidase-positive
cells in liver; ↓ serum
monocytes, TNF-a, PGE2,
NO2
[44]
Lentinula
edodes
SME 6-week nude
mice
0.1 ml water
with10%
SME/10 g
body weight
days 1-19,
33-50
50 days Injected SC prostate cancer
(PC-3) cells day 1
↓ tumor size [80]
b-glucans ♀ 3- and 8-
week BALB/c
mice (15/
group)
50, 100 or
250 μg
1-2 weeks Healthy animals 250 μg dose ↑ spleen cell IL-
2 secretion
[27]
♀ 3- and 8-
week BALB/c
mice (15/
group)
50, 100 or
250 μg
1-2 weeks Injected murine mammary
carcinoma (Ptas64) cells into
mammary fat pads 2 weeks
before treatment
↓ tumor weight
Lentinan 6-week ♂
Wistar-
Imamichi
specific-
pathogen free
rats (10/group)
1 mg twice
weekly
1-2
months
Healthy animals ↑ T cell #s, helper-cell #s &
helper/suppressor ratio, ↓
suppressor cell level at 4, but
not 8 weeks
[26]
5-6-week ♂
pre-leukemic
AKR mice (10/
group)
3 mg, days
1-7
3 weeks Injected SC K36 murine
lymphoma cells day 7
↓ tumor weight; ↑ tumor
inhibition rate (94%)
[82]
5-6-week
athymic mice
(10/group)
5 weeks Injected SC colon cancer
(LoVo and SW48, SW480 and
SW620, or SW403 and
SW1116) cells day 7
↓ tumor weight, ↑ tumor
inhibition rate (>90%)
♂ AKR mice 3 mg 1 day Pre-leukemic mice ↑ serum IFN-a and TNF-a,
peak at 4 h and then back to
normal at 24 h; ↑ IL-2 and IL-
1a, peak at 2 h and back to
normal at 24 h; ↑ CD3+ T,
CD4+ T, CD8+ T, B
lymphocytes
[81]
Phellinus linteus Aqueous,
alcohol-
precipitated
6-7-week
C57BL/6 mice
(10-50/group)
200 mg/kg
in drinking
water
1 month Healthy animals ↑ production and secretion
of IFN-g by con A stimulated
T cells
[32]
Saccharomyces
cerevisiae
Scleroglucan ♂ ICR/HSD
mice (3/group)
1 mg one
day before
challenge
(day 1)
6 days IV Staphylococcus aureus or
Candida albicans day 2
↑ long-term survival [29]
b-1,3;1,6
glucans
(particulate)
3 and 8-week
♀ BALB/c mice
(15/group)
50, 100 or
250 μg
1-2 weeks Injected murine mammary
carcinoma (Ptas64) cells into
mammary fat pads 2 weeks
before treatment
↓ tumor weight [27]
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can) [29]; and animals with fecal solution injections fed
an aqueous extract of A. subrufescens (A. blazei Murrill)
[46].
Additional controlled human and animal studies have
shown anti-inflammatory and anti-allergy effects of
some polysaccharide products. In an RCT of adults with
seasonal allergic rhinitis, S. cerevisiae b-1,3;1-6 glucans
decreased IL-4, IL-5 and percent eosinophils, and
increased IL-12 in nasal fluid [47], while a placebo-con-
trolled study of patients with recurrent aphthous stoma-
titis (canker sores) consuming b-1,3;1-6 glucans found
increased lymphocyte proliferation and decreased Ulcer
Severity Scores [48].
Animal models of inflammatory bowel disease have
shown anti-inflammatory effects of Cladosiphon
okamuranus Tokida fucoidans [49], Cyamopsis tetragono-
lobus galactomannans [50], Malus spp. pectins [51], and
mixed polysaccharide supplements [52]. Animals chal-
lenged with ovalbumin have demonstrated anti-inflamma-
tory/allergy effects of A. subrufescens aqueous extracts
[22], an aqueous extract of Ganoderma tsugae [53], and
Pyrus pyrifolia pectins [54]. Anti-inflammatory effects
have also been seen in animals with cotton pellet implan-
tations fed a Pholiota nameko heteroglycan (PNPS-1) [55].
Trametes versicolor glucans have demonstrated anti-
cancer effects in humans. In two RCTs and five con-
trolled trials, PSK from T. versicolor mycelia increased
survival of advanced stage gastric, colon and colorectal
cancer patients [56-62] with one study showing
increased immune parameters (including blood NK cell
activity, leukocyte cytotoxicity, proportion of helper cells
Table 1 Immunomodulatory Glucan Extracts: Oral Animal Studies (Continued)
b-1,3-glucan Healthy animals All 3 doses ↑ phagocytic
activity of blood monocytes
& neutrophils & ↑ spleen cell
IL-2 secretion
WT or
CCD11b
-/-
C57BL/6 mice
(2/group)
0.4 mg for 3
weeks
100 days Injected SC RMA-S-MUC1
lymphoma cells ± 14.G2a or
anti-MUC1 mAb IV injection
every 3
rd day
↓ tumor diameter when
included with mAb; ↑
survival with and without
mAb
[73]
C57BL/6mice
(4/group)
25 mg 1 week Healthy animals ↑ # intestinal IELs; ↑ # TCRab
+, TCR gδ+, CD8+, CD4+,
CD8aa+, CD8ab+ T cells in
IELs; ↑ IFN-g mRNA
expression in IELs and spleen
[28]
Sclerotinia
sclerotiorum
SSG 6-8-week
specific
pathogen-free
♂ CDF1 mice
(3/group)
40 or 80
mg/kg days
1-10
2 weeks Healthy animals 10 mg dose ↑ acid
phosphatase activity of
peritoneal Mø (day 14)
[30]
40, 80 or 160
mg/kg days
2-6
35 days Implanted SC Metha A
fibrosarcoma cells day 1
80 mg dose ↓ tumor weight
6-8-week
specific
pathogen-free
♂ CDF1 mice
(10/group)
40, 80 or 160
mg/kg days
2-11
Injected ID IMC carcinoma
cells day 1
6-8-week
specific-
pathogen free
♂ mice of
BDF1 and
C57BL/6 mice
(7/group)
0.5, 1, 2, or 4
mg days 1-
10
2-3 weeks Injected IV Lewis lung
carcinoma (3LL) cells
2m g↓ # of 3LL surface lung
nodules at 2 weeks
[83]
Sclerotium rofsii Glucan
phosphate
♂ ICR/HSD
mice (3/group)
1 mg 1 day Healthy animals ↑ systemic IL-6; ↑ Mø
expression of Dectin-1 in
GALT cells; ↑ TLR2 expression
in dendritic cells from Peyer’s
patches
[29]
Trametes
(Coriolus)
versicolor
PSP 6-8-week ♂
BALB/c mice
(10/group)
35 μg days
5-29 in
drinking
water
29 days Implanted SC Sarcoma-180
cells day 1
↓ tumor growth & vascular
density
[94]
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Extract Source Animal Oral dose/day Duration Treatment Significant effects Reference
Fucoidans Cladosiphon
okamuranus
Tokida
8-week ♀ BALB/c
mice, 10/group
0.05% w/w of
diet
56 days DSS-induced UC ↓ disease activity index and
myeloperoxidase activity; ↓
# of B220-positive colonic B
cells; ↓ colonic MLN IFN-g
and IL-6 and ↑ IL-10 and
TGF-b; ↓ colonic IgG; ↓
colonic epithelial cell IL-6,
TNF-a, and TLR4 mRNA
expression
[49]
Undaria
pinnatifida
5-week ♀ BALB/c
mice (10-12/group)
5 mg, days 1-14
or 7-14
2 weeks Injected HSV into
cornea day 7
↓ facial herpetic lesions; ↑
survival, particularly in pre-
treated animals
[45]
10 mg 1 week Administered
5-fluorouracil
↑ plasma NK cell activity
Injected SC HSV ↑ cytotoxic splenic T
lymphocyte activity
0.1 or 0.5 mg 3 weeks Injected IP HSV Both doses ↑ serum
neutralizing Ab titers,
weeks 2 and 3
6-week ♂ ddY mice
(5/group)
50, 100, 200 400
or
500 mg/kg
days 1-28
3 weeks Injected with Ehrlich
carcinoma in back
day 14
200-500 mg/kg ↓ tumor
growth
[116]
6-week ♂ BALB/c
mice (8/group)
40 mg/kg
alternating days
7-19
19 days Injected IP Meth A
fibrosarcoma day 1
↓ tumor growth
Furanose
(COLD-FX®)
Panax
quinquefolium
Weanling ♂ SD rats
(10/group)
450 or
900 mg/kg in
food
1 week Healthy animals Both doses ↑ spleen Il-2
and IFN-g production
following ConA or LPS
stimulation; ↓ proportion of
total MLN and Peyer’s
patch CD3+ cells &
activated T cells; high dose
↑ spleen cell IL-1b
production following 48 h
ConA stimulation.
[33]
Galacto-
mannan
(partially
hydrolyzed
guar gum)
Cyamopsis
tetragonolobus
10-week ♀ BALB/c
mice,
11-15/group
5% of diet 3 weeks DSS-induced UC at
beginning of
week 3
↓ disease activity index
scores, ↓ colonic mucosal
myeloperoxidase activity &
lipid peroxidation; ↓ colonic
TNF-a protein levels &
mRNA expression up
regulated by DSS exposure
[50]
Galacto-
mannans
(guar gum)
8-month- SD rats,
5/group
5% of diet 3 weeks Older animals ↓ serum IgG; ↑ MLN
lymphocyte IgA, IgM and
IgG production
[36]
Glucomannan
(KS-2)
Lentinula
edodes
DD1 mice (10-20/
group)
140 mg/kg days
2-13
50 days Injected IP Ehrlich
ascites tumor cells
day 1
↑ survival [84]
0.1, 1, 10, or 100
mg/kg dose days
2-13
100 days Injected Sarcoma-180
tumor cells
day 1
1, 10, and 100 mg/kg
doses ↑ survival
Heteroglycan
(ATOM)
A.
subrufescens
Mice (10/group): 1)
5-week ♂ Swiss/
NIH; 6 week- ♀ DS
mice; 3) 8-week ♀
BALB/c nude; 4) 5-
week C3H/HcN
100 or
300 mg/kg
days 2-11
8 weeks Implanted SC 1)
Sarcoma-180, 2)
Shionogi carcinoma
42, 3) Meth A
fibrosarcoma, or 4)
Ehrlich ascites
carcinoma cells
Both doses ↓ Sarcoma-180
tumor size at 4 weeks & ↑
survival; 300 mg/kg ↑
peritoneal macrophage and
C3-positive cells; 300 mg/
kg ↓ Shionogi and Meth A
tumor sizes at 4 weeks.
Both doses ↑ survival of
Ehrlich ascites mice
[93]
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Heteroglycan
(LBP3p)
Lycium
barbarum
♂ Kunming mice
(10/group)
5, 10 or
20 mg/kg
10 days Injected SC Sarcoma-
180 cells
5 & 10 mg/kg ↑ thymus
index; all doses ↓ weight, ↓
lipid peroxidation in serum,
liver and spleen & ↑ spleen
lymphocyte proliferation,
cytotoxic T cell activity, IL-2
mRNA
[91]
Heteroglycan
(PNPS-1)
Pholiota
nameko
SD rats (5/group) 100, 200 or 400
mg/kg days 1-8
8 days Implanted SC cotton
pellets in scapular
region
day 1
↓ granuloma growth
positively correlated with
dose: 11%, 18% and 44%,
respectively
[55]
Heteroglycan
(PG101)
Lentinus
lepideus
8-10-week ♀ BALB/
c mice (3/group)
10 mg 24 days 6 Gy gamma
irradiation
↑ colony forming cells,
granulocyte CFUs/Mø,
erythroid burst-forming
units, and myeloid
progenitor cells in bone
marrow; induced
proliferation of granulocyte
progenitor cells in bone
marrow; ↑ serum levels of
GM-CSF, IL-6, IL-1b
[92]
Mixed poly-
saccharides
(Ambrotose®
or Advanced
Ambrotose®
powders)
Aloe
barbadensis,
Larix spp, and
other plant
poly-
saccharides
♂ SD rats (10/
group)
37.7 or 377 mg/
kg Ambrotose®
powder or 57.4
or 574 mg/kg
Advanced
Ambrotose®
powder
2 weeks 5% DSS in drinking
water beginning day
6
574 mg/kg Advanced
Ambrotose powder ↓ DAI
scores; 377 mg/kg
Ambrotose complex &
both doses Advanced
Ambrotose powder ↑ colon
length and ↓ blood
monocyte count
[52]
Pectin Pyrus pyrifolia 6-8-week ♂ BALB/c
mice (11/group)
100 μg
days 1-7
22 days Injected IP OVA day
7, provoked with
OVA aerosol day 21
bronchial fluid:↓ IFN-g & ↑
IL-5; splenic cells: ↑ IFN-g, ↓
IL-5; normalized pulmonary
histopathological changes;
↓ serum IgE
[54]
Pectins
(bupleurum
2IIc)
Bupleurum
falcatum
6-8-week ♀
specific-pathogen-
free C3H/HeJ mice
250 mg/kg 1 week Healthy animals ↑ spleen cell proliferation [35]
Pectins (highly
methoxylated)
Malus spp. 8-month- SD rats
(5/group)
5% of diet vs.
cellulose control
3 weeks Older animals ↑ MLN lymphocyte IgA &
IgG
[36]
Pectins Citrus spp. 5-week ♀ F344 rats
(30/group)
15% of diet 34 weeks Injected SC AOM
once a week, weeks
4-14
↓ colon tumor incidence [86]
Malus spp. 5-week ♀ BALB/c
mice (6/group)
5% of diet 2 weeks Healthy animals ↑ fecal IgA and MLN CD4
+/CD8+ T lymphocyte ratio
& IL-2 & IFN-g secretion by
ConA-stimulated MLN
lymphocytes
[51]
5-week ♀ BALB/c
mice (6/group)
5% of diet days
5-19 vs. cellulose
control
19 days DSS-induced UC days
1-5
Significantly increased MLN
lymphocytes IgA, and
significantly decreased IgE;
significantly decreased
ConA-stimulated IL-4 and
IL-10
4-week ♂ Donryu
rats (20-21/group)
20% of diet 32 weeks Injected SC AOM
once a week,
weeks 2-12
↓ colon tumor incidence [85]
4-week ♂ Donryu
rats (19-20/group)
10 or 20% of
diet
32 weeks Injected SC AOM
once a week,
weeks 2-12
Both doses ↓ colon tumor
incidence; 20% ↓ tumor
occupied area & ↓ portal
blood and distal colon
PGE2
[90]
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Pectins
(modified)
Citrus spp. 2-4-month BALB/c
mice (9-10/group)
0.8 or 1.6 mg/ml
drinking water,
days 8-20
20 days Injected SC with 2 ×
2 mm section of
human colon-25
tumor on day 1
Both doses ↓ tumor size [87]
NCR nu/nu mice
(10/group)
1% (w/v)
drinking water
16 weeks Orthotopically
injected human
breast carcinoma
cells (MDA-MB-435)
into mammary fat
pad on day 7
↓ tumor growth rate &
volume at 7 weeks, lung
metastases at 15 weeks, #
of blood vessels/tumor at
33 days post-injection
[89]
NCR nu/nu mice
(10/group)
1% (w/v)
drinking water
7 weeks Injected human
colon carcinoma cells
(LSLiL6) into cecum
on day 7
↓ tumor weights and
metastases to the lymph
nodes and liver
SD rats (7-8/group) 0.01%, 0.1% or
1.0% wt/vol of
drinking water,
days 4-30
1 month Injected SC MAT-LyLu
rat prostate cancer
cells
0.1% and 1.0% ↓ lung
metastases; 1.0% ↓ lymph
node disease incidence
[88]
Table 3 Immunomodulatory Polysaccharide-Rich Plant Powders: Oral Animal Studies
Source Animal Oral dose/
day
Duration Treatment Significant effects Reference
Agaricus (A.
blazei)
subrufescens
(fruit bodies)
6-week ♂
C57BL/6, C3H/
HeJ and BALB/c
mice (3/group)
16, 32 or 64
mg
2 weeks Healthy animals 32 and 64 mg ↑ liver mononuclear cell
cytotoxicity
[25]
Grifola
frondosa
6-week ♀ ICR
mice (10-15/
group)
5% of diet 36 weeks Oral N-butyl-N’-
butanolnitrosamine daily for first 8
weeks
↓ #s of animals with bladder tumors; ↓
tumor weight; ↑ peritoneal Mø
chemotactic activity, splenic
lymphocyte blastogenic response &
cytotoxic activity
[70]
Laminaria
angustata
Weanling SD
rats (58/group)
5% of diet 26 weeks IG DMBA, beginning of week 5 ↑ time to tumor development and ↓ #
of adenocarcinomas in
adenocarcinoma-bearing animals
[77]
Lentinula
(Lentinus)
edodes
6-week ♀ ICR
mice (10-17/
group)
5% of diet 36 weeks Oral BBN daily for first 8 weeks ↓ # of animals with bladder tumors; ↓
tumor weight; ↑ Mø chemotactic
activity, splenic lymphocyte blastogenic
response, cytotoxic activity
[70]
7-8 -week ♂
Swiss mice (10/
group)
1%, 5% or
10% of diet of
4 different
lineages days
1-15
16 days Injected IP N-ethyl-N-nitrosourea
day 15
All 3 doses of one lineage and the 5%
dose of two other lineages ↓ #s of
micronucleated bone marrow
polychromatic erythrocytes
[79]
Lentinula
edodes (fruit
bodies)
5-week ♀ ICR
mice
(14/group × 2)
10%, 20% or
30% of diet
25 days Injected IP Sarcoma-180 ascites All 3 doses ↓ Sarcoma-180 tumor
weight
[78]
Mice: 1) CDF1;2 )
C3H; 3) BALB/c;
4,5) C57BL/6N
(9/group × 3)
20% of diet 25 days Injected SC 1) IMC carcinoma, 2)
MM-46 carcinoma, 3) Meth-A
fibrosarcoma, 4) B-16 melanoma,
or 5) Lewis lung carcinoma cells
↓ growth of MM-46, B-16, Lewis lung,
and IMC tumors; ↑ lifespan in Lewis
lung and MM-46 animals
ICR mice (14/
group × 2)
20% of diet
days 1-7, days
7-31 or days
14-31
31 days Injected IP Sarcoma-180 ascites ↓ tumor weight & growth when fed
days 7-31 or 14-31
Mice: 1) CDF1;2 )
C3 H (5/group
×4 )
20% of diet 7-12
days
Injected SC: 1) IMC carcinoma or
2) MM-46 carcinoma cells
↑ spreading rate of activated Mø ↑
phagocytic activity
Phellinus
linteus
4-week ♂ ICR
mice (10/group)
2 mg 1 month Healthy animals ↓ serum & splenocyte IgE production; ↑
proportion of splenic CD4
+ T cells &
splenocyte IFN-g production
[31]
Pleurotus
ostreatus
6-week ♀ ICR
mice
(10-20/group)
5% of diet 36 weeks Oral BBN daily for first 8 weeks ↓ #s of animals with bladder tumors; ↓
tumor weight; ↑ plasma Mø
chemotactic activity, splenic
lymphocyte blastogenic response,
cytotoxic activity
[70]
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Extract Source Study
design
Population N
(experimental/
control)
Dose/day Dura-
tion
Significant effects Reference
Arabino-
galactans
Larix
occidentalis
Randomized,
double-blind,
placebo-
controlled
Healthy adults 8/15 4 g 6
weeks
↑ % CD8+ lymphocytes &
blood lymphocyte proliferation
[18]
Arabino-
galactans
(ResistAid™)
Healthy adults
given
pneumococcal
vaccinations
day 30
21/24 4.5 g 72
days
↑ plasma IgG subtypes [19]
Fucoidans Undaria
pinnatifida
sporophylls
Randomized,
single-blind,
placebo-
controlled
Healthy adults 25 (75%
fucoidan, 6
(10%
fucoidan)/6
3g 1 2
days
75% fucoidan: ↓ #s blood
leukocytes, lymphocytes’ ↑
plasma stromal derived factor-
1, IFN-g, CD34+ cells; ↑ %
CXCR4-expressing CD34+ cells
[21]
Furanose
extract
(Cold-FX®)
Panax
quinque-
folium
Randomized,
double-blind,
placebo-
controlled
Healthy older
adults given
influenza
immunization at
the end of
week 4
22/21 400 mg 4
months
During weeks 9-16, ↓ incidence
of acute respiratory illness,
symptom duration
[20]
Glucans Agaricus
subru-
fescens
Randomized,
double-blind,
placebo-
controlled
Cervical, ovarian
or endometrial
cancer patients
receiving 3
chemotherapy
cycles
39/61 5.4 g
(estimated)
6
weeks
↑ NK cell activity, ↓
chemotherapy side effects
[64]
Glucans
(b-1,3;1,6)
Not
identified
Placebo-
controlled
Recurrent
aphthous
stomatitis
patients
31/42 20 mg 20
days
↑ PBL lymphocyte
proliferation,↓ Ulcer Severity
Scores
[48]
Glucans
(b-1,3;1-6)
S. cerevisiae Randomized,
double-blind,
placebo-
controlled
Adults with
seasonal allergic
rhinitis
12/12 20 mg 12
weeks
30 minutes after nasal allergen
provocation test, nasal lavage
fluid: ↓ IL-4, IL-5, % eosinophils,
↑ IL-12
[47]
Glucans
(PSK)
Trametes
versicolor
Randomized,
controlled
Patients with
curatively
resected
colorectal cancer
receiving
chemotherapy
221/227 200 mg 3-5
years
↑ disease-free survival and
overall survival
[56]
Controlled Post-surgical
colon cancer
patients receiving
chemotherapy
123/121 3 g for 4
weeks,
alternating
with 10 4-
week courses
of chemo-
therapy
7 years ↑ survival from cancer deaths;
no difference in disease-free or
overall survival
[57]
Post-surgical
colorectal cancer
patients receiving
chemotherapy
137/68 3 g daily 2 years ↑survival in stage III patients; ↓
recurrence in stage II & III
patients
[58]
Post-surgical
gastric cancer
patients receiving
chemotherapy
124/129 3 g for 4
weeks,
alternating
with 10 4-
week courses
of chemo-
therapy
5-7
years
↑ 5-year disease-free survival
rate, overall 5-year survival
[59]
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advanced stage lung cancer patients consuming PSP
from T. versicolor fruit bodies found increased IgG and
IgM antibodies and total leukocyte and neutrophil
counts, along with a decrease in the number of patients
withdrawing from the study due to disease progression
[63]. An RCT of ovarian or endometrial cancer patients
consuming A. subrufescens glucans showed increased
NK cell activity and fewer chemotherapy side effects
[64].
In numerous animal models of cancer, a wide range of
polysaccharides have shown anti-tumorogenic effects.
Glucan products sourced from A. subrufescens demon-
strating anti-cancer activities in animal models include
an aqueous extract [65], an aqueous, acid-treated extract
[66], and an aqueous extract with standardized levels of
b-glucans [23]. Anti-cancer effects have been reported
following intake of aqueous extracts of G. lucidum
[67-69]; the powder and D fraction of G. frondosa
[70-72]; Hordeum vulgare b-glucans [73-76]; Laminaria
angustata powder [77]; Lentinula edodes products (pow-
ders [70,78,79], SME [80], b-glucans [27], and lentinan
[81,82]); Pleurotus ostreatus powder [70], Saccharomyces
cerevisiae particulate b-1,3;1,6 and b-1,3glucans[27,73];
and a glucan from Sclerotinia sclerotiorum (SSG)
[30,83]. A glucomannan from L. edodes (KS-2) improved
survival of animals with cancer cell injections [84]; apple
and citrus pectins have exerted anti-cancer effects,
including decreased tumor incidence [85-90]. Finally,
heteroglycans from Lycium barbarum (LBP3p), Lentinus
lepidus (PG101) and A. subrufescens (ATOM) demon-
strated a number of immune stimulating effects in
animal cancer models [91-93]. Interestingly, only one
animal study has been performed using glucans from T.
versicolor (PSP): animals with cancer cell implantations
showed decreased tumor growth and vascular density
[94].
Most polysaccharide products appear to be safe, based
on NOAEL, acute and/or chronic toxicity testing in
rodents (Table 6). As would be expected, powders,
extracts and products that have not been fully character-
ized pose the most concerns. Other than for aloe vera
gel, which was shown in a small human trial to increase
the plasma bioavailability of vitamins C and E [95], the
impact of polysaccharide intake on the absorption of
nutrients and medications is not known. While one rat
toxicity study raised concerns when guar gum com-
prised 15% of the daily diet [96], the product was safe in
humans studies when 18-39.6 g/day was consumed for
up to a year (Table 4). Product contamination may
explain three case reports of hepatotoxicity and/or death
following intake of an A. subrufescens aqueous extract
[97]. Seven animal studies reporting positive immunolo-
gic effects of A. subrufescens extracts in healthy animals
or animals with cancers found no evidence of toxicity
(Tables 1 and 2). In humans, six weeks of A. subrufes-
cens glucans intake was safe for cancer patients, and
four months of 3 g/day intake by 24 healthy adults
and 24 adults with liver disease reported no evidence of
toxicity (Table 4). Another case report associated liver
toxicity with G. lucidum intake, but the elderly subject
also took an unidentified product a month previous to
her admission for testing [98]. Three animal studies
reported immunologic benefits and no adverse effects
Table 4 Immunomodulatory Polysaccharide Products: Oral Human Studies (Continued)
Pre-surgical
gastric or
colorectal cancer
patients
16 daily; 17
every other
day/13
3 g daily or on
alternate days
before surgery
<14
days or
14-36
days
≥14 day treatment: ↑
peripheral blood NK cell
activity, PBL cytotoxicity,
proportion of PBL helper cells;
↓ proportion of PBL inducer
cells; <14 day treatment: ↑ PBL
response to PSK and Con A,
proportion of regional node
lymphocyte suppressor cells
[62]
Randomized,
double-blind,
placebo-
controlled
Post-surgical
stage III-IV
colorectal cancer
patients
56/55 3 g for 2
months, 2 g
for 22 months,
1 g thereafter
8-10
years
↑ remission & survival rates [61]
Controlled Post-surgical
stage III gastric
cancer patients
receiving
chemotherapy
32/21 3 g 1 year ↑ survival time [60]
Glucans
(PSP)
Trametes
versicolor
Randomized,
double-blind,
placebo-
controlled
Conventionally-
treated stage III-
IV non-small cell
lung cancer
patients
34/34 3.06 g 1
month
↑ blood IgG & IgM, total
leukocyte and neutrophil
counts, % body fat; ↓ patient
withdrawal due to disease
progression
[63]
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Source Category Features MW Monosaccharide
composition
Reference
Agaricus subrufescens (A. blazei) Extract b-1,6-D-glucan 10,000 NA [66]
Agaricus subrufescens (fruit body) Extract a-1,6- and a-1,4 glucans with
b-1,6-glucopyranosyl backbone
(629.2 mcg/mg polysaccharides,
43.5 mcg/mg protein)
170,000 glucose [24]
a-1,4 glucans & b-1,6 glucans
with b-1,3 side branches; a-1,6
glucans; b-1,6; 1-3 glucans, b-1,4
glucans; b-1,3 glucans; b-1,6; a-
1,3 glucans; riboglucans,
galactoglucomannans, b-1,2; b-
1,3 glucomannans
NA glucose, mannose, galactose,
ribose
[25,117,118]
Agaricus subrufescens (mycelia) Extract
(ATOM)
b-1,6-D-glucan, protein
complex, 5% protein
100,000-1,000,000 glucose, mannose, galactose,
ribose
[93]
Aloe barbadensis (leaf gel) Whole tissue Dry weight: 10%
polysaccharides; acemannan,
aloemannan, aloeride, pectic
acid, galactans, arabinans,
glucomannans
average
2,000,000
mannose, glucose, galactose,
arabinose, xylose, rhamnose
[119,120]
Extract
(aloemannan)
neutral partially acetylated
glucomannan, mainly b-1,4-
mannans
>200,000 mannose, glucose [121]
Extract
(aloeride)
NA 4,000,000-
7,000,000
37% glucose, 23.9%
galactose, 19.5% mannose,
10.3% arabinose
[122]
Extract
(acemannan)
b-1,4 acetylated mannan 80,000 mannose [123]
Aloe barbadensis, (leaf gel), Larix
sp. (bark), Anogeissus latifolia
(bark), Astragalus gummifer
(stem), Oryza sativa (seed),
glucosamine
Extracts
(Ambrotose®
powder)
b-1,4 acetylated mannan,
arabinogalactans,
polysaccharide gums, rice
starch, 5.4% protein
57.3% ≥ 950,000;
26.4% < 950,000
and ≥80,000;
16.3% ≤ 10,000
mannose, galactose,
arabinose, glucose,
galacturonic acid, rhamnose,
xylose, fructose, fucose,
glucosamine, galacturonic
acid
(unpublished
data,
Mannatech
Incorporated)
Aloe barbadensis (leaf gel), Larix
sp. (bark), Undaria pinnatifida
(frond), Anogeissus latifolia (bark),
Astragalus gummifer (stem),
Oryza sativa (seed), glucosamine
Extracts
(Advanced
Ambrotose®
powder)
b-1,4 acetylated mannan,
arabinogalactans,
polysaccharide gums, fucoidans,
rice starch, 6% protein, 1% fatty
acids
13% = 1,686,667;
46% = 960,000
30% <950,000
and ≥70,000;
11% ≤ 10,000
Avena spp. (seed endosperm) Extract b-1,3;1,4 particulate (1-3 μ)
glucans
1,100,000 glucose [43]
Avena spp. (seed) Extract b-1,4,1,3 particulate glucans
(linear chains of b-D-
glycopyranosyl units; 70% b 1-4
linked)
2,000,000 NA [41,124]
Buplerum falcatum (root) Extract
(bupleuran
2IIc)
6 linked galactosyl chains with
terminal glucuronic acid
substituted to b-galactosyl
chains
NA galactose, glucuronic acid,
rhamnose
[35]
Citrus spp. (fruit) Extract a-1,4-linked partially esterified
D-anhydrogalacturonic acid
units interrupted periodically
with 1,2-rhamnose
70,000-100,000 galactose, galacturonic acid,
arabinose, glucose, xylose,
rhamnose
[125]
Cladosiphon okamuranus (frond) Extract a-1,3-fucopyranose sulfate 56,000 fucose:glucuronic acid
(6.1:1.0)
[126]
Cordyceps sinensis (mycelia) Extract b-1,3-D-glucan with 1,6-
branched chains
NA NA [127]
Cyamopsis tetragonolobus (seed) Extract (guar
gum)
Main chain of b-1,4-
mannopyranosyl units with
a-galactopyranosyl units
220,000 mannose, galactose [36,128]
Ramberg et al. Nutrition Journal 2010, 9:54
http://www.nutritionj.com/content/9/1/54
Page 12 of 22Table 5 Immunomodulatory Polysaccharide Products: Composition and Structure (Continued)
Extract
(partially-
hydrolyzed
guar gum)
NA 20,000 mannose, galactose [50]
Flammulina velutipes Extract NA NA glucose, mannose, galactose [117]
Flammulina velutipes (fruit body) Extract b-1,3 glucan NA glucose [129]
Ganoderma lucidum Whole tissue Linear b-1,3-glucans with
varying degrees of
D-glucopyranosyl branching,
b-glucan/protein complexes,
heteropolysaccharides
400,000-1,000,000 glucose, galactose, mannose,
xylose, uronic acid
[130]
Extract NA 7,000-9,000 NA [67]
Ganoderma lucidum (fruit body) Extract NA 7,000-9,000 NA
b-linked heteroglycan peptide 513,000 fructose, galactose, glucose,
rhamnose, xylose (3.167:
0.556:6.89:0.549:3.61)
[15]
Ganoderma tsugae Extract 55.6% carbohydrates (12.5%
polysaccharides); 12%
triterpenes, 1.7% sodium, 0.28%
protein, 0% lipid
NA NA [53]
Ginkgo biloba (seed) Extract 89.7% polysaccharides NA glucose, fructose, galactose,
rhamnose
[131]
Grifola frondosa Whole tissue b-1,3; 1, 6-glucans, a-glucans,
mannoxyloglucans, xyloglucans,
mannogalactofucans
NA glucose, fucose, xylose,
mannose, galactose
[117]
Grifola frondosa (fruit body) Extract
(D fraction)
b-1,6-glucan with b-1,3
branches, 30% protein
NA glucose [132]
Extract
(X fraction)
b-1,6-D-glucan with a-1,4
branches, 35% protein
550,000-558,000 glucose
Hordeum spp. (seed) Extract b-1,3;1,4-and b-1,3;1,6-D-glucans 45,000-404,000 glucose [75]
Primarily linear b-1,3;1,4-
glucans
NA glucose [124]
Laminaria spp.
(frond)
Extract
(laminarin)
b-1,3;1-6 glucan 7,700 glucose [29]
b-1,3 glucan with some b-1,6
branches and a small amount
of protein
4,500-5,500 glucose [44]
Extract Fucoidan NA NA [133]
Larix occidentalis (bark) Extract b-1,3;1,6-D-galactans with
arabinofuranosyl and
arabinopyranosyl side chains
19,000-40,000 galactose:arabinose (6:1),
uronic acid
[128,134]
Lentinula edodes Extract (SME) b-1,3-glucans (4-5%), a-1,4-
glucan (8-10%), protein
(11-14%)
NA glucose [80]
Extract b-glucan 1,000 glucose [27]
Whole tissue Linear b-1,3-glucans, b-1,4;1,6-
glucans, heterogalactan
NA glucose, galactose, mannose,
fucose, xylose
[135]
Extract
(lentinan)
b-1,3-glucan with 2 b-1,6
glucopyranoside branchings for
every 5 b-1,3-glucopyranoside
linear linkages
500,000 glucose [136]
Lentinula edodes (fruit body)
Lentinula edodes
Extract
(lentinan)
Neutral b-1,3-D glucan with two
b-1,6 glucoside branches for
every five b-1,3 units
400,000-800,000 glucose [137]
Extract
(KS-2)
Peptide units and mannan
connected by a-glycosidic
bonds
60,000-90,000 mannose, glucose
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Lentinula edodes (mycelia or fruit
body)
Extract Triple helical b-1,3-D glucan
with b-1,6 glucoside branches
1,000,000 glucose [3]
Lentinula edodes (mycelia) Extract
(LEM)
44% sugars, 24.6% protein ~1,000,000 xylose, arabinose, glucose,
galactose, mannose, fructose
[3]
Extract
(PG101)
72.4% polysaccharides, 26.2%
protein, 1.4% hexosamine
NA 55.6% glucose, 25.9%
galactose, 18.5% mannose
[138]
Lycium barbarum Whole tissue a-1,4;1,6-D-glucans, lentinan,
b-1,3;1,6 heteroglucans,
heterogalactans,
heteromannans, xyloglucans
NA glucose, galactose, mannose,
xylose
[139]
Lycium barbarum (fruit body) Extract
(LBP3p)
88.36% sugars, 7.63% protein 157,000 galactose, glucose,
rhamnose, arabinose,
mannose, xylose (molar ratio
of 1:2.12:1.25:1.10:1.95:1.76)
[91]
Panax quinquefolium (root) Extract Poly-furanosyl-pyranosyl
saccharides
NA arabinose, galactose,
rhamnose, galacturonic acid,
glucuronic acid
[33]
NA NA glucose, mannose, xylose [140]
Extract
(Cold-fX®)
90% poly-furanosyl-pyranosyl-
saccharides
NA furanose [20]
Phellinus linteus (fruit body) Extract a- and b-linked 1,3 acidic
proteoglycan with 1,6 branches
150,000 glucose, mannose, arabinose,
xylose
[141]
Phellinus linteus (mycelia) Extract 83.2% polysaccharide (4.4%
b-glucan), 6.4% protein, 0.1% fat
NA glucose [142]
Pholiota nameko (fruit body) Extract (PNPS-
1)
NA 114,000 mannose, glucose, galactose,
arabinose, xylose (molar ratio
of 1:8.4:13.6:29.6:6.2)
[55]
Pleurotus ostreatus (mycelia) Extract b-1,3;1,6-D-glucans 316,260 glucose [143]
Saccharomyces cerevisiae Extract (WGP) Particulate b-1,3;1,6-D-glucan NA glucose [144]
Extract b-glucans with b-1,6 branches
with a b-1,3 regions
NA glucose [124]
Extract
(SBG)
soluble b-1,3-D-glucan with
b-1,3 side chains attached with
b-1,6 linkages
20,000 glucose [145]
Sclerotinia sclerotiorum (mycelia) Extract
(SSG)
b-1,3-D-glucan, <1% protein
(>98% polysaccharide)
NA glucose [83]
Sclerotium rofsii Extract
(scleroglucan)
b-1,3;1,6 glucan 1,000,000 glucose [29]
Trametes versicolor (fruit body) Extract
(PSP)
a-1,4, b-1,3 glucans, 10%
peptides
100,000 glucose, arabinose, mannose,
rhamnose
[146]
Trametes versicolor (mycelia) Extract
(PSK)
b-1,4;1,3;1,6-D-glucans, protein 94,000 glucose (74.6%), mannose
(15.5%), xylose (4.8%),
galactose (2.7%), fucose
(2.4%)
[137,147]
Undaria pinnatifida (sporophyll) Extract Galactofucan sulfate 9,000 fucose:galactose 1.0:1.1 [148]
Galactofucan sulfate 63,000 fucose:galactose:gluc-uronic
acid (1.0:1.0:0.04)
[149]
b-1,3-galactofucan sulphate 38,000 fucose, galactose [150]
Unidentified source Extract
(modified
citrus pectin)
NA 10,000 galactose, rhamnose, uronic
acid
[125]
Extract (highly
methoxylated
pectin)
NA 200,000 NA [36]
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Page 14 of 22Table 6 Safety of Immunomodulatory Polysaccharide Products Following Oral Intake
Category Source Test group Test Design Results Equivalent
human
dose*
Reference
Arabino-
galactans
Argemone
mexicana
(arabinogalactan
protein)
Pregnant rats Develop-
mental
toxicity
250, 500, or 1,00
mg/kg, gestational
days 5-19
No developmental toxicity:
NOAEL = 1 g/kg
68 g [151]
♀ and ♂ rats Fertility 250, 500, or 1,00
mg/kg, 1 month
No effects on reproduction:
NOAEL = 1 g/kg
Fucoidans Undaria
pinnatifida
Rats Subchronic
toxicity
1.35 g/kg, 1
month
No evidence of toxicity 91.8 g [152]
Galacto-
mannans
Cyamopsis
tetragonolobus
Adolescent and
adult ♂ rats
Subchronic
and chronic
toxicity
8% of diet, 6-67
weeks
No evidence of toxicity 8% of diet [153]
Rats Acute
toxicity
One 7.06 g/kg
dose: observed 2
weeks
LD50 = 7.06 g/kg 480 g [96]
Subchronic
and chronic
toxicity
1, 2, 4, 7.5 or 15%
of diet, 3 months
All doses ↓ ♀ BW; 7.5-15% ↓ ♂
BW; 15% ↓ bone marrow
cellularity; ↓ kidney and liver
weights
1-15% of
diet
19 adults with
hypercholesterol-
emia
18 g/day, 1 year Short-term gastric bloating/loose
stools, in 8 subjects, resolved in
7-10 days; 2 withdrew because of
diarrhea. No toxicity for 13
subjects completing study
18 g [154]
16 Type II
diabetics
26.4-39.6 g/day, 6
months
No effects on hematologic,
hepatic, or renal function
39.9 g [155]
18 Type II
diabetics
30 g/day, 4
months
30 g
Cyamopsis
tetragonolobus
(partially
hydrolyzed guar
gum)
Mice & rats Acute
toxicity
One 6 g/kg dose;
observed
2 weeks
LD50 > 6 g/kg >408 g [156]
Rats Subchronic
toxicity
0.2, 1.0 or 5% of
diet, 13 weeks
No evidence of toxicity 5% of diet
0.5 or 2.5 g/kg, 1
month
NOAEL > 2.5 g/kg >170 g [157]
S. typhimurium Mutagenicity Ames test Not mutagenic NA
Glucans Agaricus
subrufescens
(aqueous extract)
Rats Subchronic
toxicity
0.63, 1.25, 2.5 or
5% of diet, 3
months
NOAEL = 5% of diet 5% of diet [158]
3 women with
advanced
cancers
Case reports Specific identity of
products, doses,
and durations of
intake unknown
Severe hepatotoxicity; two
patients died
NA [97]
Agaricus
subrufescens
(freeze dried
powder)
24 normal adults
and 24 adults
with liver
problems
Subchronic
toxicity
3 g, 4 months No evidence of toxicity 3 g [159]
Ganoderma
lucidum
(supplement)
Elderly woman Case report 1 year G. lucidum
(and another
unidentified
product, initiated
one month
previous)
Elevated liver enzymes and liver
tissue damage
NA [98]
Grifola frondosa
(powder)
Rats Acute
toxicity
One 2 g/kg dose No evidence of toxicity 136 g [160]
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Page 15 of 22following intake of G. lucidum aqueous extracts; in one
study intake was 5% of the diet for 5 months (Table 1).
While adverse effects were also reported in a study in
which 10 adults consumed 4 g/day L. edodes powder for
10 weeks [99], immunologic animal studies reported no
ill effects of either L. edodes powder (5 studies, up to 5%
of the diet up to nine months) or extract (7 studies, up
to 40 days intake) (Tables 1 and 3). Finally, while intake
of 319 mg/kg of an aqueous extract of P. ostreatus by
mice for 1 month caused hemorrhages in multiple tis-
sues [100], there was no reported toxicity when mice
consumed the mushroom powder as 5% of their diet for
nine months (Table 3). While ≥1g r a m / d a yo fT.
versicolor glucan products were safely consumed by can-
cer patients for up to 10 years, the long-term effects of
ingestion of the other polysaccharide products discussed
in this review is also not known.
Discussion
The majority of studies that qualified for inclusion in
this review employed models investigating immune sti-
mulation; fewer explored anti-inflammatory effects. Ani-
mal studies reported immune system effects in the gut,
spleen, bone marrow, liver, blood, thymus, lungs, and
saliva; controlled human studies reported evidence of
immune stimulation in the blood, anti-inflammatory
Table 6 Safety of Immunomodulatory Polysaccharide Products Following Oral Intake (Continued)
Lentinula edodes
(powder)
10 adults Safety 4 g/day for 10
weeks; repeated
3-6 months later
50% of subjects experienced
blood eosinophilia, ↑ eosinophil
granule proteins in serum and
stool, ↑GI symptoms
4 g [99]
Lentinula edodes
(SME)
Nude mice Safety 10% of diet days
1-18, 33-50
No adverse events 10% of diet [80]
61 men with
prostate cancer
0.1 g/kg, 6 months No adverse events 6.8 g
Lentinus lepideus
(PG101)
Female mice Subchronic
toxicity
0.5 g/kg, 24 days No evidence of toxicity 34 g [92]
Phellinus linteus
(crude extract)
Rats Acute
toxicity
One 5 g/kg dose;
observed
2 weeks
LD50 > 5 g/kg 349 g [161]
Pleurotus
ostreatus
(aqueous extract)
Mice Acute
toxicity
One 3 g/kg dose;
observed
1 day
LD50 > 3 g/kg >204.g [100]
Subacute
toxicity
319 mg/kg,
1 month
Hemorrhages in intestine, liver,
lung, kidney; inflammation and
microabscesses in liver
21.7 g
Saccharomyces
cerevisiae
(particulate
glucan [WGP])
Rats Acute
toxicity
One 2 g/kg,
observed 2 weeks
LD50 > 2 g/kg >136 g [144]
Subchronic
toxicity
2, 33.3 or 100 mg/
kg, 3 months
NOAEL = 100 mg/kg 6.80 g
Heteroglycans Trametes
versicolor
(PSP)
Rats Subchronic
toxicity
1.5, 3.0 or 6.0 mg/
kg, 2 months
No evidence of toxicity 408 mg [162]
Rats & monkeys Subchronic
and chronic
toxicity
100-200X
equivalent human
dose, 6 months
No evidence of toxicity NA
Trametes
versicolor
(PSK)
Humans with
colon cancer
Safety 3 g/day, up to
7 years
No significant adverse events 3 g [57]
Humans with
colorectal cancer
3 g/day, 2 years 3 g [58]
Mannans Aloe vera gel Dogs Acute
toxicity
Fed one 32 g/kg;
observed 2 weeks
LD50 > 32 g/kg >2,176 g Bill Pine,
personal
communi-
cation
Rats One 21.5 g/kg;
observed 2 weeks
LD50 > 10 g/kg >680 g
*150 lb adult
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Page 16 of 22effects in nasal lavage fluid and improved survival in
cancer patients. The literature is highly heterogenous
and is not sufficient to support broad structure/function
generalizations. For the limited number of studies that
investigated well-characterized, isolated products (pri-
marily glucan products), effects can be unequivocally
attributed to polysaccharides. Such associations are cer-
tainly more tenuous when considering product powders
or products obtained by extraction methods designed to
isolate polysaccharides, but without complete composi-
tional analyses.
Dietary polysaccharides are known to impact gut
microbial ecology [101,102], and advances in microbial
ecology, immunology and metabolomics indicate that gut
microbiota can impact host nutrition, immune modula-
t i o n ,r e s i s t a n c et op a t h o g e n s ,i ntestinal epithelial devel-
opment and activity, and energy metabolism [103-107].
Other than fucoidans, the polysaccharides discussed in
this review appear to be at least partially degraded by
bacterial enzymes in the human digestive tract (Table 7).
Arabinogalactans, galactomannans, a glucan (laminarin),
glucomannans, and mixed polysaccharide products
(Ambrotose® products) have been shown to be metabo-
lized by human colonic bacteria. Orally ingested fucoi-
dans, glucans and mannans (or their fragments) have
been detected in numerous tissues and organs through-
out the body [73,108,109], (Carrington Laboratories, per-
sonal communication). We know of no study that has
determined the specific identity of orally-ingested poly-
saccharide end products in animal or human tissues.
One can only speculate upon the mechanisms by
which the polysaccharides discussed in this review influ-
ence immunologic function, particularly when one con-
siders the exceedingly complex environment of the GI
tract. It is possible that fragments of polysaccharides
partially hydrolyzed by gut bacteria may either bind to
gut epithelia and exert localized and/or systemic
immune system effects, or be absorbed into the blood-
stream, with the potential to exert systemic effects. Cur-
rent studies investigating the link between the
bioconversion of dietary polysaccharides, their bioavail-
ability and their downstream effects on the host
Table 7 Fate of Immunomodulatory Polysaccharide Products Following Oral Intake
Category Product Metabol-ized
by human gut
bacteria?
Study
type
Fate
(method: tissues detected)
References
Arabinogalactans Larix spp. yes in vitro NA [163-169]
Fucoidans Undaria pinnatifida no in vitro Ab: human plasma [108,170]
Galactomannans Cyamopsis tetragonolobus
(partially hydrolyzed guar gum)
yes in vivo NA [171]
Cyamopsis tetragonolobus (guar
gum)
yes in vitro NA [167]
Glucans Hordeum vulgare NA in vivo Fluorescein-labeled: mouse Mø in the spleen,
bone marrow, lymph nodes
[73]
Laminaria digitata (laminarin) yes in vitro NA [29,170,172]
Sclerotium rofsii (scleroglucan)
glucan phosphate, Laminaria
spp. (laminarin)
NA in vivo Alexa Fluor 488-labeled: mouse intestinal
epithelial cells, plasma, GALT
[29]
Saccharomyces cervisiae
(particulate)
NA in vivo Fluorescein-labeled: mouse macrophage in
the spleen, bone marrow, lymph nodes
[73]
Trametes versicolor
(PSK)
NA in vivo
14C-labeled: rat and rabbit serum; mouse GI
tract, bone marrow, salivary glands, liver,
brain, spleen, pancreas
[173]
Mannans Aloe barbadensis (aloemannan) yes in vitro FITC-labeled: mouse, GI tract [121,174]
Aloe barbadensis
(gel powder)
yes in vitro NA [163]
Aloe barbadensis (acemannan) NA in vivo
14C-labeled: dog systemic, particularly liver,
bone marrow, gut, kidney, thymus, spleen
(Carrington
Laboratories,
personal
communication)
Mixed
polysaccharide
products
Ambrotose complex®,
Advanced Ambrotose® powder
yes in vitro NA [163,175]
Pectins NA yes in vitro NA [165-167,176]
Buplerum falcatum (bupleuran
2IIc)
NA in vivo Ab bound: mouse Peyer’s patch, liver [109]
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Page 17 of 22metabolism and physiology are utilizing metabolomic
and metagenomic approaches that can detect and track
diverse microbial metabolites from immunomodulatory
polysaccharides [103]. These and other innovative
approaches in the field of colonic fermentation are pro-
viding novel insights into gut microbial-human mutual-
ism [110,111], its impact on regulating human health
and disease, and the importance of dietary modulation
[112-115].
Additional RCTs of well-characterized products are
needed to more completely understand the immunomo-
dulatory effects and specific applications of oral polysac-
charides. Such studies will need to better investigate the
optimal timing and duration for polysaccharide inges-
tion. That is, should they be consumed continuously,
before, at the time of, or after exposure to a pathogen
or environmental insult? Only a few studies have actu-
ally investigated the impact of timing of polysaccharide
intake to achieve optimal benefits. Daily feeding with
some polysaccharides appears to result in tolerance (and
diminished benefits); this has been demonstrated for
some mushroom b-glucans [3,26]. For those polysac-
charides whose immunologic effects are dependent on
their prebiotic activities, regular feeding would be pre-
sumed necessary.
Conclusions
The dietary polysaccharides included in this review have
been shown to elicit diverse immunomodulatory effects
in animal tissues, including the blood, GI tract, and
spleen. In controlled human trials, polysaccharide intake
stimulated the immune system in the blood of healthy
adults, dampened the allergic response to a respiratory
inflammatory agent, and improved survival in cancer
patients. Additional RCTs of well-characterized products
are needed to more completely understand the immuno-
modulatory effects and specific applications of oral
polysaccharides
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